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Abstract 2 
The mechanisms governing corpus luteum (CL) function in domestic dogs remain not fully 3 
elucidated. The upregulated expression of cyclooxygenase 2 (COX2) and prostaglandin (PG) 4 
E2 synthase (PGES) at the beginning of the canine luteal phase indicated their luteotrophic 5 
roles and the steroidogenic activity of PGE2 in the early canine CL has been confirmed in 6 
vitro. Recently, by applying a COX2 specific inhibitor (firocoxib, Previcox®, Merial) from the 7 
day of ovulation until the mid-luteal phase, the luteotrophic effects of prostaglandins have 8 
been shown in vivo. This is a follow-up study investigating the underlying endocrine 9 
mechanisms associated with the firocoxib-mediated effects on the canine CL. Experimental 10 
groups were formed with ovario-hysterectomies performed at days 5, 10, 20 or 30 of 11 
firocoxib-treatments (10mg/kg bw/24h; TGs = treated groups). Untreated dogs served as 12 
controls. A decrease of STAR protein expression was observed in TGs. The expression of 13 
PGES was significantly suppressed in TGs 5 and 10, and both PGE2 and PGF2α levels were 14 
decreased in luteal homogenates, particularly from CLs in TG 5. Similarly, expression of the 15 
prolactin receptor (PRLR) was diminished in TGs 5 and 20. The expression of PGE2-16 
receptors PTGER2 (EP2) and PTGER4 (EP4), the PG-transporter (PGT) and 15-PG-17 
dehydrogenase (HPGD) was not affected in TGs. Our results substantiate a direct luteotrophic 18 
role of PGs in the early canine CL, i.e., by upregulating the steroidogenic machinery. 19 
Additionally, the possibility of an indirect effect on PRL function arises from the increased 20 
PRLR expression in response to PGE2 treatment in canine lutein cells observed in vitro.  21 
 22 
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Introduction 26 
The mechanisms regulating luteal establishment and maintenance in the domestic dog (Canis 27 
familiaris) are still not well understood. Following the strong preovulatory luteinisation and 28 
ovulation, the canine corpus luteum (CL) develops from residual follicular cells. Cell 29 
populations known to contribute to luteal development in other species, i.e., cells of the 30 
follicular wall-associated granulosa and the theca interna, likely contribute to the formation of 31 
the mature canine CL, even though there is no distinction between small and large lutein cells 32 
(reviewed in (13)). The central role of the CL in regulating canine reproduction is due to the 33 
fact that, in both pregnant and nonpregnant dogs, CLs are the only source of progesterone 34 
(P4) and are thus responsible for the establishment and maintenance of pregnancy. This is in 35 
contrast to other carnivores like felids, where progesterone of placental origin has been 36 
recently suggested as an additional source of progesterone (2,26). Specific to the dog is also 37 
the lack of a uterine luteolysin of endometrial origin (9,24), which in absence of pregnancy 38 
can result in a luteal life span exceeding that observed during pregnancy (9).  39 
Whereas during the second half of the luteal phase the canine CL strongly depends on 40 
hypophyseal support, with PRL being the crucial luteotrophic hormone as early as day 25 41 
after the preovulatory LH peak (22,23,25), early luteal development appears to be 42 
characterized by a period of transitional gonadotropic independence (12,13,23). During this 43 
time, locally produced (intra-CL) prostaglandins (PGs) appear to be amongst the most 44 
important luteotrophic factors. Thus, formation of the canine CL is associated with increased 45 
cyclooxygenase 2 (COX2, PTGS2) and PGE2-synthase (PGES, PTGES) expression 46 
(14,19,21), accompanying progressively increasing expression levels of the steroidogenic 47 
acute regulatory (STAR) protein and 3β-hydroxysteroid-dehydrogenase (3βHSD, HSD3B2) 48 
and dynamically rising circulating P4 levels. In line with these findings, we were able to show 49 
that the PTGES-derived PGE2 significantly upregulates P4 synthesis in canine luteal cells 50 
isolated from the early CL (15). This effect seems to be mediated at the level of STAR-51 
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dependent steroid substrate provision, rather than at the level of enzymatic activity of 3βHSD 52 
and P450 side-chain cleavage enzyme (P450scc, CYP11A1), as concluded from their 53 
unaltered expression in response to treatment with PGE2. Similar effects were observed in 54 
other species, such as pig, sheep and human (3,7,29), in which PGE2 positively affected P4 55 
production by acting through the cAMP/PKA pathway, which is the main cell signalling route 56 
involved in STAR-mediated steroidogenesis. The luteotrophic efficiency of PGE2 has been 57 
shown to be similar to that of LH (29). 58 
Most recently, in experiments applying a selective COX2 (PTGS2) inhibitor (firocoxib, 59 
Previcox®, Merial) during the early canine dioestrus phase, compelling in vivo evidence has 60 
been provided for luteotrophic effects of PGs in the canine CL (11). In dogs treated for up to 61 
30 days after ovulation with this compound, inhibition of the steroidogenic apparatus was 62 
achieved. This was clearly indicated by significantly reduced areas of luteal cell nuclei, 63 
decreased expression of 3βHSD, and lower mean P4 concentrations in treated dogs.  64 
In order to gain additional information on the underlying endocrine mechanisms associated 65 
with the firocoxib-mediated effects on canine CL, the present experiments assessed the effects 66 
of firocoxib on the luteal expression of STAR, COX2 (PTGS2), PTGES and their respective 67 
PGE2 receptors, EP2 (PTGER2) and EP4 (PTGER4), 15-hydroxyprostaglandin 68 
dehydrogenase (HPGD, the enzyme responsible for enzymatic deactivation of PGs) and 69 
prostaglandin transporter (PGT, SLCO2A1). In parallel, the luteal content of PGE2 and 70 
PGF2α was measured. Furthermore, since known luteotrophic hormones could potentially 71 
modulate each other’s functions, the expression of PRL-receptor (PRLR), LH-receptor (LHR) 72 
and the progesterone receptor (PGR) was investigated.  73 
Additionally, taking into account the role of PRL as the main luteotrophic factor during the 74 
second half of canine dioestrus, and the recently presented evidence showing increasing 75 
expression of its receptor during the early luteal phase (18), the expression of PRLR was 76 
investigated by assessing mRNA obtained from primary luteal cells isolated during the early 77 
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luteal phase, which had been treated with PGE2 in previous experiments (15).  78 
 79 
Material and Methods 80 
Tissue sampling 81 
Tissue materials were the same as those used in our previous study (11). All animal 82 
experiments were approved by the responsible ethics committee of the University of Warmia 83 
and Mazury in Olsztyn, Poland. 84 
In total, thirty (n=30) bitches of various breeds aged 2-7 years were used for the present 85 
study. They were randomly divided into four experimental groups with ovario-hysterectomy 86 
performed on days 5 (n=4), 10 (n=3), 20 (n=3) and 30 (n=3) of the treatment and designated 87 
as TGs (treatment groups 1-4, respectively). During the treatment periods, dogs received 10 88 
mg/kg daily of firocoxib (a highly selective COX2 inhibitor marketed as Previcox® by Merial 89 
Ltd.), which was double the recommended dose of 5 mg/kg body weight per day. Ovario-90 
hysterectomies were performed on the last day of treatment. Additionally, untreated dogs 91 
received a placebo and served as controls (CGs = control groups). Five CGs were designated: 92 
days 0 (n=3), 5 (n=5), 10 (n=3), 20 (n=3) and 30 (n=3) post ovulation (p.o.). Day 0 was the 93 
day of ovulation, determined as the day when peripheral P4 reached levels >5 ng/ml, as 94 
measured every two days using a commercially available chemiluminescence kit 95 
(Progesteroene II®, Roche Diagnostics, Mannheim, Germany). Additionally, the oestrous  96 
cycle stage was monitored by examination of vaginal smears. Blood samples were collected 97 
every 2 days following ovulation during the entire duration of the experiments for continuous 98 
P4 measurements and stored at -200 C until evaluation. The P4 concentrations are presented 99 
elsewhere (11).  100 
Following ovario-hysterectomy, CLs were trimmed of connective tissue and cut into small 101 
pieces. Subsequently, one piece was preserved for RNA isolation by incubation for 24 h at 102 
+4OC in RNAlater® (Ambion Biotechnology GmbH, Wiesbaden, Germany) and then stored at 103 
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-80OC until RNA isolation. Another piece of the tissue material was fixed for 24 h at +4OC 104 
with 10% phosphate-buffered formalin and paraffin-embedded using a standard procedure.  105 
 106 
Primary luteal cell cultures 107 
The mRNA obtained from a previous study (15) was used in the present experiments to gain 108 
additional information on PRLR mRNA expression in canine lutein cells in response to 109 
PGE2-treatment. In that study, canine primary lutein cells were isolated from 15 healthy 110 
bitches submitted for routine ovario-hysterectomies, which were performed during the early 111 
luteal phase, 7-14 days after the clinical signs of heat had ceased. Briefly, 0.15% Collagenase 112 
(Sigma-Aldrich Chemie GmbH, Buch, CH) was applied to isolate cells from luteal tissues 113 
collected from each animal. A 75µm cell strainer (BD Biosciences, Basel, CH) was used to 114 
remove undissociated tissue fragments. After washing in culture medium (DMEM/F12, pH 115 
7.2-7.4 with 10% heat-inactivated FBS, 100U/ml penicillin and 100µg/ml streptomycin, and 116 
1% ITS; all from Chemie Brunschwig AG, Basel, CH), cells were suspended in culture 117 
medium and seeded directly into 6-well plates and cultured in a humidified incubator at 37oC 118 
under 5% CO2 in air. Importantly, the cells were not passaged (trypsinized) prior to the 119 
experiments: “passage 0” cells were used. Cells were treated in serum-free medium. The 120 
steroidogenic identity of the isolated cells had been confirmed by performing anti-3βHSD and 121 
anti-STAR immunoflorescence staining. When stimulated for 6 h with either 0.5 mM N6,2-122 
dibutyryladenosine-3,5-cyclic monophosphate (dbcAMP; used for positive control) or 20 µM 123 
PGE2 (both Sigma-Aldrich Chemie GmbH, Buchs, Switzerland), cells exhibited upregulated 124 
expression of STAR mRNA and protein, as well as strongly increased P4 output. 125 
 126 
Reverse Transcription (RT), real time (TaqMan) PCR and data evaluation 127 
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TRIzol® reagent (Invitrogen, Carlsbad, CA, USA) was used to isolate total RNA according to 128 
the instructions of the manufacturer. The concentration of RNA was determined with a 129 
NanoDrop 2000C® spectrophotometer (Thermo Fisher Scientific AG, Reinach, Switzerland). 130 
In order to remove any potential genomic DNA contamination frequently occurring with the 131 
use of TRIzol®, prior to reverse transcription (RT), all samples were DNase-treated using 132 
RQ1 RNase-free DNase (Promega, Dübendorf, Switzerland), following the supplied protocol. 133 
For RT reaction, random hexamers were used as primers, which together with other reagents 134 
for cDNA synthesis, were purchased from Applied Biosystems (Foster City, CA, USA). Our 135 
previously published standard RT protocol was applied (21). All reactions were conducted in 136 
an Eppendorf Mastercycler® (Vaudaux-Eppendrf AG, Basel, Switzerland). The conditions 137 
applied were as follows: 8 min at 21°C, 15 min at 42°C, finally for 5 min at 99°C to stop the 138 
enzymatic reaction. 139 
The luteal expression of target genes was semi-quantified by real time (TaqMan) PCR 140 
performed in an automated ABI PRISM 7500 Sequence Detection System (Applied 141 
Biosystems), with the previously published protocol and the manufacturer’s instructions 142 
(17,21). For all samples, cDNA corresponding to 200 ng of total RNA per sample was used in 143 
duplicate in 96-well optical plates (Applied Biosystems). Fast Start Universal Probe Master 144 
(ROX®) (Roche Diagnostics AG, Switzerland) was used in reactions that were run under the 145 
following conditions: denaturation at 95 °C for 10 min, 40 cycles at 95°C for 15 sec and 60°C 146 
for 60 sec. Water instead of cDNA and the so-called RT minus control (i.e., samples that were 147 
not reverse-transcribed) were run as negative controls. 148 
Three reference genes, GAPDH, 18SrRNA and cyclophilin, were used in the comparative CT 149 
method (ΔΔCT method) according to the instructions of the ABI 7500 Fast Real-Time PCR 150 
System manufacturer and as described previously (17,21). By applying the CT slope method, 151 
PCR reactions were set up to achieve approximately 100% reaction efficiency. Selected PCR 152 
products were sent for commercial sequencing (Microsynth, Balgach, Switzerland). The 153 
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primers and 6-carboxyfluorescein (6-FAM)- and 6-carboxytetramethyl-rhodamine 154 
(TAMRA)-labelled TaqMan probes were designed using Primer Express Software (Version 155 
2.0, Applied Biosystems) and purchased from Microsynth (Table 1). The canine-specific 156 
cyclophilin A TaqMan gene Expression Assay used was obtained commercially from Applied 157 
Biosystems (Prod. No. Cf03986523_gH). 158 
 159 
Immunohistochemical expression of STAR and PRLR 160 
The standard immunoperoxidase immunohistochemistry (IHC) protocol was applied 161 
according to our previously published procedure (16,18). Primary antisera were: rabbit 162 
polyclonal anti-STAR (a gift from Dr. DM Stocco, Texas Tech University Health Sciences 163 
Center, Lubbock, TX, USA; (4)) used at 1:3000 dilution, and polyclonal goat antigen affinity-164 
purified IgG fraction against human PRLr (R&D Systems Europe Ltd), dilution 1:50. Serum 165 
from non-immunized rabbit or goat IgG irrelevant antibodies I-5000, from Vector 166 
Laboratories Inc., Burlingame, CA940101, CA, USA, served as negative/isotype controls, 167 
respectively. Depending on the primary antiserum, 10% horse serum or 10% normal goat 168 
serum was used for blocking of nonspecific binding sites. Secondary antibodies were: goat 169 
anti-rabbit IgG BA-1000 and horse anti-goat IgG BA-9500, both from Vector Laboratories 170 
Inc. (Burlingame, CA, USA), used at 1:100 dilution. Signals were enhanced with avidin-171 
biotin-peroxidase complex (Vector Laboratories Inc.) and detected using a Liquid DAB+ 172 
substrate kit (Dako Schweiz AG, Baar, Switzerland). Sections were counterstained with 173 
hematoxylin and embedded in Histokit (Assistant, Osterode, Germany) 174 
 175 
Luteal PGE2 and PGF2α  extraction and determination 176 
Extraction of luteal prostaglandins was done according to the previously described protocol 177 
(27). Briefly, luteal fragments weighing 30-50 mg were stored at -80°C. After thawing, each 178 
tissue sample was homogenized in a glass vial using a tissue disruptor with 400 µl of a Tris 179 
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buffered saline containing proteins and sodium azide as preservative, acidified by addition of 180 
45 µl 1 N HCl. After adding 3 ml of ethyl ether to the samples, they were vortexed for 10 min 181 
and incubated at -20°C for 4 h. Afterwards, the supernatant was collected and evaporated to 182 
dryness under a stream of nitrogen at 40°C. Finally, 400 µl of the Tris buffered saline was 183 
added, mixed and allowed to sit for 15 min at 20°C. The samples were stored at -20°C until 184 
the immunoassay was run.  185 
For PGF2α and PGE2 measurements, the commercial PGF2α high sensitivity EIA kit and the 186 
PGE2 high sensitivity EIA kit (both from ENZO Life Sciences Inc., Farmingdale, NY, USA) 187 
were used, and run according to the manufacturer’s instructions.  188 
The sensitivity of the PGF2α assay was 0.98 pg/ml. The cross-reactivity for various PGs and 189 
their metabolites was as follows: PGF2α 100%, PGF1α 11.82%, PGD2 3.62%, 6-keto-190 
PGF1α 1.38%, PGI2 1.25% and PGE2 0.77%. The inter- and intra-assay variation 191 
coefficients were 10.8% and 8.6%, respectively. The sensitivity of the PGE2 assay was 8.26 192 
pg/ml. The cross-reactivity for various prostaglandins and their metabolites was as follows: 193 
PGE2 100%, PGE1 70%, PGE3 16.3%, PGF1α 1.4%, PGF2α 0.7% and 6-keto-PGF1α 0.6%. 194 
The inter- and intra-assay variation coefficients were 12.2% and 6.9%, respectively. 195 
 196 
Statistical evaluation 197 
Due to the uneven distribution of the real time PCR data, the geometric means (Xg) and 198 
deviation factors (DF) were calculated for the analysis of target gene expression. The PGE2 199 
and PGF2α data are presented as the mean ± SD. The Kruskal-Wallis Test (a nonparametric 200 
ANOVA) followed by Dunn’s Multiple Comparisons Test was applied for testing the effects 201 
of time on mRNA levels in all control samples (CGs). The effects of time on concentrations 202 
of PGE2 and PGF2α were calculated using one-way analysis of variance (ANOVA) followed 203 
by Tukey-Kramer Multiple Comparisons Test applied for testing the effects of time on 204 
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hormone levels in all control samples (CGs). In order to test for the effects of treatments, an 205 
unpaired two-tailed Student’s t-test was performed; numerical data are presented either as Xg 206 
± DF or mean ± SD. For all tests, the statistical software program GraphPad 3.06 (GraphPad 207 
Software Inc., San Diego, CA, USA) was used. P < 0.05 was considered statistically 208 
significant. 209 
 210 
Results 211 
Histological assessment of (peri)ovulatory canine follicles 212 
Histological analysis of haematoxylin-eosin stained tissue cross sections confirmed that 213 
ovulation was in progress at day 0 (day of ovulation, P4 > 5ng/ml). Both freshly ovulated and 214 
preovulatory follicles were found (Fig. 1). The latter ones revealed advanced preovulatory 215 
luteinisation characterized by strong follicular wall folding. Morphological changes were 216 
clearly visible within the theca interna layers, the cells of which changed shape from 217 
elongated to rounded. The blood vessels containing luteinizing theca layers were separated 218 
from the follicular granulosa cells by clearly distinguishable basement membranes. Following 219 
ovulation, further luteinisation of theca interna cells, as well as luteinisation of granulosa 220 
cells, and remnants of the basement membranes were observed.  221 
 222 
Semi-quantitation of gene expression 223 
The expression of target genes was detectable in all tissue material available for the study. A 224 
significant effect of time was observed for the mRNA expression of STAR (P<0.04), COX2 225 
(PTGS2) (P<0.04), PTGES (PGES) (P<0.03), EP2 (PTGER2) (P<0.01), EP4 (PTGER4) 226 
(P<0.01), HPGD (P<0.01) and PRLR (P<0.01) in control samples (CG) from ovulation 227 
throughout early dioestrus (Fig. 2 and 3). The expression of PGT, LHR and PGR did not 228 
differ significantly over time (P>0.05) (Fig. 3). The expression of STAR and PGES increased 229 
significantly (P<0.05) following ovulation, reaching the highest levels at day 5 p.o.. Their 230 
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expression remained statistically unaltered thereafter (Fig. 2). Similar effects were observed 231 
for luteal PRLR expression, which was significantly (P<0.05) upregulated in CGs 5 and 20 232 
compared with the day of ovulation (Fig. 3). The expression of COX2 and of the two PGE2 233 
receptors, EP2 and EP4, which was strongly elevated at the beginning of the luteal phase, 234 
continued to decrease towards the mid-luteal phase and was significantly (P<0.05) 235 
downregulated at day 20 and/or 30 after ovulation (Fig. 2). The opposite effect was noted for 236 
HPGD with values continuously increasing from ovulation until the end of the observation 237 
period in CG 30 (P<0.05) (Fig. 2). 238 
Similar to what was observed for most of the CGs, there was a high individual variability in 239 
expression of genes following treatment with Previcox®. The expression of STAR, PGES and 240 
PRLR was negatively affected by this treatment (Fig. 2 and 3). This effect was significant for 241 
STAR mRNA expression in TG 5 (P<0.03), TG 20 (P<0.04) and TG 30 (P<0.02). The PGES 242 
mRNA abundance was significantly suppressed in TG 5 (P<0.03) and TG 10 (P<0.04) and 243 
that of PRLR in TG 5 (P<0.01) and TG 20 (P<0.04).  244 
As for STAR and PRLR, similar effects to those observed at the mRNA level were observed 245 
for expression of their respective proteins. These were detectable in all 246 
immunohistochemically examined samples; the evenly distributed signals were localized to 247 
the cytoplasm of lutein cells and appeared to be weaker when COX2 function, and thereby the 248 
supply of prostaglandins, was compromised in Previcox®-treated dogs (Fig. 4 and 5).  249 
The expression of other members of the prostaglandin family, i.e., COX2, EP2, EP4, HPGD 250 
and PGT, as well as of LHR and PGR, remained unaffected by the treatment (P>0.05) (Fig. 2 251 
and 3).  252 
The expression of PRLR was significantly upregulated in PGE2-treated lutein cells in vitro 253 
(P<0.05) (Fig. 3F). 254 
 255 
Luetal PGE2 and PGF2α  content 256 
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There was a significant (P<0.02) time effect observed for the luteal content of both PGE2 and 257 
PGF2α throughout the course of the experiment (Fig. 6). Their concentrations were strongly 258 
elevated in the CLs forming at ovulation with 394.9 ± 152.9 pg/mg tissue and 505.4 ± 94.5 259 
pg/mg tissue for PGE2 and PGF2α, respectively. Whereas the PGF2α content was reduced 260 
after ovulation to 5.7 ± 1.7 pg/mg tissue, PGE2 remained high in early developing CLs at day 261 
5 p.o. with 354.6 ± 140 pg/mg tissue. As presented in Fig. 6, the PGE2 concentration 262 
determined in luteal homogenates was significantly reduced in TG 5 (P<0.04) and TG 10 263 
(P<0.05) of Previcox®-treated dogs. Similarly, the PGF2α content was further decreased in 264 
TG 5 (P<0.03).  265 
 266 
Discussion  267 
Morphologically and ultrastructurally, only one type of steroidogenic cell, displaying a high 268 
content of both endoplasmic reticulum and mitochondria (8), is present in the canine CL. 269 
Consequently, its cellular origin and the extent to which either of the cell types in the original 270 
population (i.e., theca interna and granulosa) contribute to luteal formation have been subjects 271 
of continuous scientific debate (e.g., (5,13)). Our histological analysis of canine ovarian 272 
tissues during ovulation revealed the presence of strongly luteinized preovulatory follicles as 273 
well as freshly-ovulated follicles. The post-ovulatory development was characterized by 274 
intense ingrowth of luteinizing theca interna cells accompanied by blood vessels. Within the 275 
inner part of the former follicle (i.e., the antrum folliculare), luteinizing granulosa cells were 276 
observed, still separated from theca cells by remnants of basement membrane and not yet 277 
associated with blood vessels. Thus, this observation on the presence of luteinizing granulosa 278 
cells in the early canine CL provides a new insight into canine luteal physiology, even though 279 
the process of development of the uniform luteal cell population still remains to be elucidated.  280 
 13 
Unequivocally, prostaglandins are among the most important and versatile factors regulating 281 
CL function in mammals. In dogs, the role of intraluteal PGs seems to be strongly linked to 282 
luteal formation rather than to luteolysis (14,21). This idea has been further strengthened by 283 
results obtained in the present study. Hence, expression of the so-called PG family members 284 
resembled their previously reported expression patterns (6,14,19), with early luteal 285 
development being characterized by increased expression of COX2 (PTGS2), PGES, 286 
PTGER2, PTGER4 and PGT, and gradually increasing HPGD expression towards mid-287 
dioestrus. As a consequence thereof, increased availability of luteotrophic PGE2 is observed 288 
locally, i.e., within the CL, as shown in the present study. This, in turn, leads to increased 289 
STAR protein expression and steroidogenic output.  290 
The PGFS/AKR1C3, which is the only-known canine-specific isoform of PGF2α synthase, 291 
responsible for the direct conversion of PGH2 to PGF2α (6), is either absent or expressed at a 292 
very low level in the canine CL throughout dioestrus (14,20). This fact, in line with results 293 
obtained in the present study, is reflected in the very low PGF2α production within the CL, 294 
which is not sufficient to affect normal luteal function, even though PGF2α is luteolytic in 295 
dogs.  296 
Whereas development of the CL was associated with low PGF2α but increased PGE2 297 
content, the concentration of both PGs was high during ovulation, implicating their 298 
involvement in this process, and resembling the situation described in other species (10,28). 299 
In addition to the recently described impairment of steroidogenic machinery in dogs treated 300 
with firocoxib during early dioestrus (11), in the present study, potential regulatory 301 
mechanisms involved in this process were investigated. Blocking COX2 decreased PGES 302 
expression and consequently reduced the PGE2 content in the CL, thereby impairing STAR 303 
mRNA and protein expression. This further indicates causality between the expression and 304 
functioning of these entities. It is noteworthy that functional coupling between COX2 and 305 
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PGES expression for PGE2 production, even though still not fully elucidated, was previously 306 
observed in the brains of COX2-deficient mice (1). Interestingly, the expression and, 307 
presumably, the function of the respective PGE2 receptors, PTGER2 and PTGER4, as well as 308 
of PGT and HPGD, remained unaffected.  309 
Making use of the availability of the partial canine-specific PRLR sequence cloned in our 310 
laboratory (18), corresponding to the homologous portions of the extra- and trans-membrane 311 
domains conserved in PRLR isoforms of other species, the impact of firocoxib on its 312 
expression was investigated. Inhibition of COX2 significantly suppressed PRLR expression, 313 
both at the mRNA and protein levels. Considering the function of PRL as the main 314 
luteotrophic factor in the mature canine CL (22) and the possible role of its receptor as an 315 
upstream regulator of STAR and/or 3βHSD expression (18), this is an interesting finding 316 
since decreased expression of the PRLR might result in reduced sensitivity of the CL to 317 
circulating PRL. The possible functional interrelationship between PGE2 and PRLR 318 
expression is also surmised from the increased expression of PRLR-mRNA in PGE2-treated 319 
canine luteal cells isolated from early CLs. However, before any final conclusion can be 320 
drawn, the complete cDNA of canine PRLR and its potential isoforms need to be elucidated.  321 
The high individual variability noted for the expression of target genes, especially in response 322 
to treatment with Previcox®, may be indicative of compensatory mechanisms existing within 323 
the canine CL and thus merits further investigations, possibly involving larger groups of 324 
experimental animals.  325 
 326 
Following up on our recent in vivo studies providing functional evidence for the luteotrophic 327 
role of prostaglandins within the early canine CL, in this study the first insight is presented 328 
into the underlying endocrine and molecular regulatory mechanisms. The previously 329 
postulated (14,15,19) causality between the COX2 and the PGES-dependent synthesis of 330 
PGE2 regulating STAR protein expression and function has now been clearly shown. 331 
 15 
Thereby, the direct role of PGE2 in regulating early canine CL function, as characterized by 332 
decreased sensitivity towards gonadotrophic stimuli, has been further substantiated. 333 
Moreover, as indicated by in vivo and in vitro experiments (using canine lutein cell cultures), 334 
PGE2 seems to be involved indirectly in the PRL-mediated maintenance of canine CL 335 
function by potentiating PRLR expression. The latter pathway is a new regulatory mechanism 336 
not previously described for species, such as cattle and pigs, in which LH, and to a lesser 337 
extent PRL, is essential for luteal maintenance. 338 
 339 
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Figure 1 442 
Haematoxylin-eosin (HE) staining of canine (peri)ovulatory follicles, before ovulation 443 
(shown at lower and higher magnification) and after ovulation. Open arrowheads = blood 444 
vessels, solid arrowheads = basement membrane, open arrows = granulosa cells before 445 
ovulation and during luteinization (after ovulation), solid arrows = luteinizing theca interna 446 
cells, red arrowhead = cumulus-oocyte complex.   447 
 448 
Figure 2 449 
Expression of STAR, COX2, PGES, EP2 (PTGER2), EP4 (PTGER4) and HPGD as 450 
determined by semi-quantitative Real Time (TaqMan) PCR in luteal tissue samples of control 451 
(cont.) and Previcox® (Prev.)-treated dogs (Xg x DF±1). Kruskal-Wallis Test followed by 452 
Dunn’s Multiple Comparison Test was applied to test the effects of time on gene expression 453 
in all control samples (dashed lines indicate P<0.05). Student’s t-test was applied to test the 454 
effect of treatment on gene expression: (*) indicates P<0.02, (**) indicates P<0.03 and (***) 455 
indicates P<0.04.  456 
 457 
Figure 3 458 
Expression of PGT, LHR, PGR and PRLR as determined by semi-quantitative Real Time 459 
(TaqMan) PCR in (A-D) luteal tissue samples of control (cont.) and Previcox® (Prev.)-treated 460 
dogs (Xg x DF±1) and (E) PRLR expression in canine primary luteal cells collected from non-461 
pregnant dogs during the early luteal phase and treated with PGE2. Untreated cells served as 462 
negative controls. Cell culture experiments were performed independently at least three times 463 
using cells isolated from different animals. The Kruskal-Wallis Test followed by Dunn’s 464 
Multiple Comparison Test was applied to test the effects of time on gene expression in all 465 
control samples (dashed lines in “D” indicate P<0.05). Student’s t-test was applied to test the 466 
 19 
effect of treatment on gene expression. Bars with (*) differ at P<0.01, bars with (**) differ 467 
with P<0.04 and bars with (***) differ at P<0.05.  468 
 469 
Figure 4 470 
Immunohistochemical localisation of STAR protein in canine luteal samples in control and 471 
Previcox®-treated dogs. Representative pictures are shown for days 5, 20 and 30 after 472 
ovulation (p.o.). Positive staining is localized in cytoplasm of lutein cells.  473 
 474 
Figure 5 475 
Immunohistochemical localisation of PRLR in canine luteal samples in control and 476 
Previcox®-treated dogs. Representative pictures are shown for days 5 and 20 after ovulation 477 
(p.o.). Positive staining is localized in cytoplasm of lutein cells.  478 
 479 
Figure 6 480 
Concentrations of PGE2 and PGF2α in luteal homogenates of control (cont.) and Previcox® 481 
(Prev.)-treated dogs measured by EIA assay (pg/mg tissue; mean ± SD). One-way ANOVA 482 
followed by Tukey-Kramer Multiple Comparison Test was applied to test the effects of time on 483 
hormone concentrations in all control samples (dashed lines indicate P<0.05). Student’s t-test 484 
was applied to test the effect of treatment on hormone concentration: (*) indicates P<0.03, 485 
(**) indicates P<0.04 and (***) indicates P<0.05.  486 
 487 
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Primer Accession 
numbers 
Primer Sequence Product 
 lenght (bp) 
GAPDH (forward) 
GAPDH (reverse) 
GAPDH (TaqMan Probe)  
AB028142 
 
5'-GCT GCCAAATAT GAC GAC ATC A-3' 
5'-GTA GCC CAG GAT GCC TTT GAG-3'  
5'-TCC CTC CGA TGC CTG CTT CAC TAC CTT-3' 
75bp 
 
18SrRNA (forward) 
18SrRNA (reverse) 
18SrRNA (TaqMan Probe) 
FJ797658 
 
5'-GTC GCT CGC TCC TCT CCT ACT-3' 
5'-GGC TGA CCG GGT TGG TTT-3' 
5'-ACA TGC CGA CGG GCG CTG AC-3' 
125bp 
 
STAR (forward) 
STAR (reverse) 
STAR (TaqMan Probe) 
EF522840 
 
5'- CGA GGC TCC ACC TGT GTG T-3' 
5'- CCT TTC TGC TCA GGC ATC TC-3', 
5'- CTG GCA TGG CCA CAC ATT TC-3 
 65bp 
 
PGES (forward) 
PGES (reverse) 
PGES (TaqMan Probe) 
NM_001122854 5'-GTC CTG GCG CTG GTG AGT -3' 
5'- ATG ACA GCC ACC ACG TAC ATC T-3' 
5'-TCC CAG CCT TCC TGC TCT GCA GC -3' 
 89bp 
 
PTGER2 (EP2) (forward) 
PTGER2 (EP2) (reverse) 
PTGER2 (EP2) (TaqMan Probe) 
AF075602 
 
5'- CAC CCT GCT GCT GCT TCT C-3' 
5'- CGG TGC ATG CGG ATG AG-3' 
5'-TGC TCG CCT GCA ACT TTC AGC GTC -3' 
 78bp 
 
PTGER4 (EP4) (forward) 
PTGER4 (EP4) (reverse) 
PTGER4 (EP4) (TaqMan Probe) 
NM_001003054 
 
5'- AAA TCA GCA AAA ACC CAG ACT TG-3' 
5'-GCA CGG TCT TCC GCA GAA -3' 
5'-ATC CGA ATT GCT GCT GTG AAC CCT ATC C -3' 
 96bp 
 
COX2 (forward) 
COX2 (reverse) 
COX2 (TaqMan Probe) 
HQ110882 
 
5'- GGA GCA TAA CAG AGT GTG TGA TGT G-3' 
5'- AAG TAT TAG CCT GCT CGT CTG GAA T-3' 
5'- CGC TCA TCA TCC CAT TCT GGG TGC -3' 
87bp 
PGT (forward) 
PGT (reverse) 
PGT (TaqMan probe) 
NM_001011558 
 
5′-TGC AGC ACT AGG AAT GCT GTT C-3′ 
5′-GGG CGC AGA GAA TCA TGG A-3′ 
5′-TCT GCA AAC CAT TCC CCG CGT G-3′ 
 116bp 
 
HPGD (forward) 
HPGD (reverse) 
HPGD (TaqMan Probe) 
NM_001284477 
 
5'-GGC AGC GAA TCT CAT GAA CAG-3' 
5'- TCT TCT TTC TCA ATG GAT TCA AGGA-3' 
5'- TGA ATG CCA TTT GCC CAG GCT TTG-3' 
93bp 
 
PRLr (forward) 
PRLr (reverse) 
PRLr (TaqMan Probe) 
HQ267784 
 
5'-GGA TCT TTG TGG CCG TTC TTT-3' 
5'-AAG GAT GCA GGT CAC CAT GCT AT-3' 
5'-ATT ATG GTC GTA GCA GTG GCT TTG AAA GGC-3' 
 92bp 
 
PGR (forward) 
PGR (reverse) 
PGR (TaqMan Probe) 
NM_001003074 
 
5'-CGA GTC ATT ACC TCA GAA GAT TTG TTT -3' 
5'- CTT CCA TTG CCC TTT TAA AGA AGA-3' 
5'- AAG CAT CAG GCT GTC ATT ATG GTG TCC TAA CTT-3' 
 113bp 
 
LHR (forward) 
LHR (reverse) 
LHR (TaqMan Probe)  
XM538486 
 
5'- TCA TCA TTT GTG CTT GCT ACA TTA AA-3' 
5'- CGC CAT TTT CTT AGC AAT CTT TG-3' 
5'- TGC AGT TCA AAA TCC AGA GCT GAT GGC-3' 
 98bp 
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